Search hospitals > Pennsylvania > Philadelphia
Children's Hospital of Philadelphia
Claim this profilePhiladelphia, Pennsylvania 19104
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Brain Tumor
Conducts research for Post Intensive Care Syndrome
Conducts research for Acute Lymphoblastic Leukemia
1798 reported clinical trials
169 medical researchers
Summary
Children's Hospital of Philadelphia is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Brain Tumor, Post Intensive Care Syndrome, Acute Lymphoblastic Leukemia and other specialties. Children's Hospital of Philadelphia is involved with conducting 1,798 clinical trials across 1,852 conditions. There are 169 research doctors associated with this hospital, such as Theodore W. Laetsch, Frank M Balis, Michael J Fisher, MD, and Nancy J Bunin, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
NTRK positive
2Adult T-Cell Leukemia/Lymphoma
Global LeaderCD19 positive
BCR-ABL1 positive
Stage II
Top PIs
Theodore W. LaetschChildren's Hospital of Philadelphia2 years of reported clinical research
Expert in Cancer
Expert in Soft Tissue Sarcoma
32 reported clinical trials
48 drugs studied
Frank M BalisChildren's Hospital of Philadelphia8 years of reported clinical research
Expert in Cancer
Expert in Soft Tissue Sarcoma
20 reported clinical trials
39 drugs studied
Michael J Fisher, MDChildren's Hospital of Philadelphia5 years of reported clinical research
Expert in Gliomas
Expert in Brain Tumor
18 reported clinical trials
29 drugs studied
Nancy J Bunin, MDChildren's Hospital of Philadelphia7 years of reported clinical research
Studies Primary Immunodeficiency
Studies Glut1 Deficiency Syndrome
15 reported clinical trials
18 drugs studied
Clinical Trials running at Children's Hospital of Philadelphia
Crohn's Disease
Testicular cancer
Acute Lymphoblastic Leukemia
Kidney Disease
Anemia of Chronic Kidney Disease
Chronic Kidney Disease
Adult T-Cell Leukemia/Lymphoma
Wilms Tumor
Sepsis
Autism Spectrum Disorder
Mirikizumab
for Pediatric Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits.
Recruiting2 awards Phase 3
Guselkumab
for Pediatric Crohn's Disease
This trial tests guselkumab, an anti-inflammatory medication, on children with Crohn's Disease who initially responded well to it. The goal is to see if the benefits last over several months by reducing immune system activity. Guselkumab has shown effectiveness in treating moderate-to-severe psoriasis and psoriatic arthritis.
Recruiting2 awards Phase 3
Upadacitinib
for Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being developed for moderate- to severely active CD in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: a 12-week open-label induction phase which means that the study doctor and participants know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 52-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given(UPA Dose B or Dose C). Period 2 is a 156-week open-label extension of Period 1. Approximately 110 pediatric participants with moderate to severely active CD will be enrolled at approximately 92 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will have a safety follow up for 30 days after discontinuation from any time point within the study. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 32 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's Hospital of Philadelphia?
Children's Hospital of Philadelphia is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Brain Tumor, Post Intensive Care Syndrome, Acute Lymphoblastic Leukemia and other specialties. Children's Hospital of Philadelphia is involved with conducting 1,798 clinical trials across 1,852 conditions. There are 169 research doctors associated with this hospital, such as Theodore W. Laetsch, Frank M Balis, Michael J Fisher, MD, and Nancy J Bunin, MD.
Where is Children's Hospital of Philadelphia located?
**Children's Hospital of Philadelphia**
- **Address:** 3401 Civic Center Blvd, Philadelphia, PA 19104
- **Public Transit Options:** Buses, subways, and trains are available. The nearest light rail station is Lancaster Av & 44th St, approximately a 19-minute walk from the hospital.
Who should I call to ask about financial aid or insurance network?
1. For assistance with applying for the Family Health Coverage Program at CHOP, contact their office to speak with a Family Health Coverage Coordinator.
2. St. Christopher's Hospital for Children offers financial assistance. Inquiries can be made at 484-628-5683.
3. Shriners Children's provides financial assistance and accepts most private insurance plans. Visit their Financial Assistance page for more details.
4. CHOP's Medical Financial Partnership program offers free tax preparation and financial counseling at their Karabots Pediatric Care Center in West Philly.
What insurance does Children's Hospital of Philadelphia accept?
**Insurance Plans Accepted at The Children's Hospital of Philadelphia:**
- **General:** Aetna, AmeriHealth, Blue Cross Blue Shield, CHAMP Va, Geisinger Health Plan.
- **Harborview/Smithville Primary Care:** Aetna Choice POS, Choice POS II, Elect Choice, Blue Cross Blue Shield, CHAMP Va.
- **Voorhees Specialty Care Center:** Aetna, AmeriHealth, Geisinger Health Plan, Oxford – Liberty and Freedom (medical diagnosis only).
- **CHOP Medical Plans:** Consumer Directed Health Plan, CHOP Preferred Care Plan, Keystone/AmeriHealth HMO Plan.
What awards or recognition has Children's Hospital of Philadelphia received?
The Children's Hospital of Philadelphia Research Institute is a leading recipient of NIH funding for pediatric research. It has been awarded a $50 million NIH grant to explore the effects of environmental factors on pregnancy and children's health.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.